Edwards Lifesciences Co. (NYSE:EW) Shares Acquired by Pittenger & Anderson Inc.

Pittenger & Anderson Inc. increased its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 59.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 15,014 shares of the medical research company’s stock after acquiring an additional 5,609 shares during the quarter. Pittenger & Anderson Inc.’s holdings in Edwards Lifesciences were worth $1,111,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of EW. Alpha Financial Partners LLC acquired a new position in shares of Edwards Lifesciences during the 3rd quarter valued at about $693,000. Blue Trust Inc. increased its position in Edwards Lifesciences by 59.4% during the third quarter. Blue Trust Inc. now owns 8,049 shares of the medical research company’s stock worth $531,000 after purchasing an additional 2,998 shares during the last quarter. Resonant Capital Advisors LLC raised its stake in Edwards Lifesciences by 6.3% during the third quarter. Resonant Capital Advisors LLC now owns 3,132 shares of the medical research company’s stock worth $207,000 after purchasing an additional 186 shares during the period. Telos Capital Management Inc. boosted its holdings in shares of Edwards Lifesciences by 1.6% in the 3rd quarter. Telos Capital Management Inc. now owns 98,894 shares of the medical research company’s stock valued at $6,526,000 after purchasing an additional 1,519 shares during the last quarter. Finally, Eastern Bank purchased a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at $98,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Edwards Lifesciences news, Director Steven R. Loranger sold 5,739 shares of the business’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $76.42, for a total transaction of $438,574.38. Following the completion of the transaction, the director now directly owns 60,372 shares of the company’s stock, valued at $4,613,628.24. The trade was a 8.68 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 500 shares of the firm’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the sale, the vice president now owns 23,189 shares in the company, valued at $1,594,475.64. The trade was a 2.11 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 26,489 shares of company stock valued at $2,002,829 over the last quarter. Insiders own 1.29% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on EW. The Goldman Sachs Group lifted their target price on Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, December 5th. Sanford C. Bernstein raised Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research note on Monday, October 28th. Barclays increased their target price on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 13th. Evercore ISI decreased their price objective on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a research note on Wednesday, February 12th. Finally, Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and raised their target price for the company from $82.00 to $90.00 in a research note on Monday, December 16th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, Edwards Lifesciences has an average rating of “Hold” and a consensus target price of $79.95.

Edwards Lifesciences Price Performance

Shares of EW opened at $76.23 on Tuesday. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The firm has a market cap of $44.96 billion, a price-to-earnings ratio of 11.00, a PEG ratio of 3.64 and a beta of 1.10. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The stock has a 50 day moving average of $72.67 and a 200-day moving average of $69.58.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. As a group, analysts forecast that Edwards Lifesciences Co. will post 2.56 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.